Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials

Seungtae Kim, Kyoung Mee Kim, Nayoung K.D. Kim, Joonoh Park, Soomin Ahn, Jae Won Yun, Kyu Tae Kim, Sehoon Park, Peter J. Park, Heecheol Kim, Taesung Sohn, Dong Il Cho, Jongho Cho, Jinseok Heo, Woo Il Kwon, Hyuk Lee, Byung Hoon Min, Sung No Hong, Youngsuk Park, Hoyeong LimWonki Kang, Woong Yang Park, Jeeyun Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable “precision medicine,” wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancerrelated genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.

Original languageEnglish
Pages (from-to)1169-1177
Number of pages9
JournalOncologist
Volume22
Issue number10
DOIs
StatePublished - Oct 2017

Fingerprint

High-Throughput Nucleotide Sequencing
Biomarkers
Clinical Trials
Neoplasms
Urogenital Neoplasms
Biliary Tract Neoplasms
Precision Medicine
Neoplasm Genes
Gene Fusion
Sarcoma
Quality Control
Stomach Neoplasms
Colorectal Neoplasms
Nucleotides
Mutation
Therapeutics

Keywords

  • Clinical trials
  • Metastatic cancer
  • Molecular screening
  • Next-generation sequencing

Cite this

Kim, Seungtae ; Kim, Kyoung Mee ; Kim, Nayoung K.D. ; Park, Joonoh ; Ahn, Soomin ; Yun, Jae Won ; Kim, Kyu Tae ; Park, Sehoon ; Park, Peter J. ; Kim, Heecheol ; Sohn, Taesung ; Cho, Dong Il ; Cho, Jongho ; Heo, Jinseok ; Kwon, Woo Il ; Lee, Hyuk ; Min, Byung Hoon ; Hong, Sung No ; Park, Youngsuk ; Lim, Hoyeong ; Kang, Wonki ; Park, Woong Yang ; Lee, Jeeyun. / Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials. In: Oncologist. 2017 ; Vol. 22, No. 10. pp. 1169-1177.
@article{713af8a0396f4334b1962b026ddd39c0,
title = "Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials",
abstract = "Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable “precision medicine,” wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancerrelated genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12{\%}) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44{\%}) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.",
keywords = "Clinical trials, Metastatic cancer, Molecular screening, Next-generation sequencing",
author = "Seungtae Kim and Kim, {Kyoung Mee} and Kim, {Nayoung K.D.} and Joonoh Park and Soomin Ahn and Yun, {Jae Won} and Kim, {Kyu Tae} and Sehoon Park and Park, {Peter J.} and Heecheol Kim and Taesung Sohn and Cho, {Dong Il} and Jongho Cho and Jinseok Heo and Kwon, {Woo Il} and Hyuk Lee and Min, {Byung Hoon} and Hong, {Sung No} and Youngsuk Park and Hoyeong Lim and Wonki Kang and Park, {Woong Yang} and Jeeyun Lee",
year = "2017",
month = "10",
doi = "10.1634/theoncologist.2017-0020",
language = "English",
volume = "22",
pages = "1169--1177",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

Kim, S, Kim, KM, Kim, NKD, Park, J, Ahn, S, Yun, JW, Kim, KT, Park, S, Park, PJ, Kim, H, Sohn, T, Cho, DI, Cho, J, Heo, J, Kwon, WI, Lee, H, Min, BH, Hong, SN, Park, Y, Lim, H, Kang, W, Park, WY & Lee, J 2017, 'Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials', Oncologist, vol. 22, no. 10, pp. 1169-1177. https://doi.org/10.1634/theoncologist.2017-0020

Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials. / Kim, Seungtae; Kim, Kyoung Mee; Kim, Nayoung K.D.; Park, Joonoh; Ahn, Soomin; Yun, Jae Won; Kim, Kyu Tae; Park, Sehoon; Park, Peter J.; Kim, Heecheol; Sohn, Taesung; Cho, Dong Il; Cho, Jongho; Heo, Jinseok; Kwon, Woo Il; Lee, Hyuk; Min, Byung Hoon; Hong, Sung No; Park, Youngsuk; Lim, Hoyeong; Kang, Wonki; Park, Woong Yang; Lee, Jeeyun.

In: Oncologist, Vol. 22, No. 10, 10.2017, p. 1169-1177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials

AU - Kim, Seungtae

AU - Kim, Kyoung Mee

AU - Kim, Nayoung K.D.

AU - Park, Joonoh

AU - Ahn, Soomin

AU - Yun, Jae Won

AU - Kim, Kyu Tae

AU - Park, Sehoon

AU - Park, Peter J.

AU - Kim, Heecheol

AU - Sohn, Taesung

AU - Cho, Dong Il

AU - Cho, Jongho

AU - Heo, Jinseok

AU - Kwon, Woo Il

AU - Lee, Hyuk

AU - Min, Byung Hoon

AU - Hong, Sung No

AU - Park, Youngsuk

AU - Lim, Hoyeong

AU - Kang, Wonki

AU - Park, Woong Yang

AU - Lee, Jeeyun

PY - 2017/10

Y1 - 2017/10

N2 - Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable “precision medicine,” wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancerrelated genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.

AB - Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable “precision medicine,” wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancerrelated genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.

KW - Clinical trials

KW - Metastatic cancer

KW - Molecular screening

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85034042262&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0020

DO - 10.1634/theoncologist.2017-0020

M3 - Article

C2 - 28701572

AN - SCOPUS:85034042262

VL - 22

SP - 1169

EP - 1177

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -